Ann Qin

发表

Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development.

Dolores Diaz, Jianping Yin, Michael Burkard, 2016, Journal of medicinal chemistry.

Organic Anion Transporting Polypeptide Inhibition Dramatically Increases Plasma Exposure but not Pharmacodynamic Effect nor Inferred Hepatic Intracellular Exposure of Firsocostat

Mun Sang Yue, A. Mathias, B. Kearney, 2020, Clinical pharmacology and therapeutics.

Use of Transgenic Mouse Models to Understand the Oral Disposition and Drug-Drug Interaction Potential of Cobimetinib, a MEK Inhibitor

E. Choo, J. Ly, Ann Qin, 2015, Drug Metabolism and Disposition.

Nanosuspension delivery of paclitaxel to xenograft mice can alter drug disposition and anti-tumor activity

Po-Chang Chiang, Stephen Gould, Harvey Wong, 2014, Nanoscale Research Letters.

A reversed sulfonamide series of selective RORc inverse agonists.

Bohdan Waszkowycz, Emanuela Gancia, Peter Lockey, 2014, Bioorganic & medicinal chemistry letters.

Highly selective c-Jun N-terminal kinase (JNK) 3 inhibitors with in vitro CNS-like pharmacokinetic properties II. Central core replacement.

R. Neitz, H. Sham, T. Yednock, 2011, Bioorganic & medicinal chemistry letters.

Utility of CYP3A4 and PXR-CAR-CYP3A4/3A7 Transgenic Mouse Models To Assess the Magnitude of CYP3A4 Mediated Drug-Drug Interactions.

E. Choo, J. Ly, Ann Qin, 2017, Molecular pharmaceutics.

The Relative Bioavailability and Effects of Food and Acid‐Reducing Agents on Filgotinib Tablets in Healthy Subjects

Y. Xin, Ann Qin, Kacey B. Anderson, 2019, Clinical pharmacology in drug development.

Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models.

Leslie B. Lee, D. Sampath, P. Jackson, 2013, Neoplasia.

Lack of Drug‐Drug Interaction Between Filgotinib, a Selective JAK1 Inhibitor, and Oral Hormonal Contraceptives Levonorgestrel/Ethinyl Estradiol in Healthy Volunteers

R. Begley, A. Mathias, B. Kearney, 2020, Clinical pharmacology in drug development.

Filgotinib, a JAK1 Inhibitor, Has No Effect on QT Interval in Healthy Subjects

A. Mathias, B. Kearney, Y. Xin, 2019, Clinical pharmacology in drug development.

In Vitro and In Vivo Evaluation of Amorphous Solid Dispersions Generated by Different Bench-Scale Processes, Using Griseofulvin as a Model Compound

Y. Ran, J. Lubach, H. Wong, 2013, The AAPS Journal.

Collagenase as an effective tool for drug quantitation in tissues.

Ann Qin, S. Shahidi-Latham, B. Dean, 2015, Bioanalysis.

Highly selective c-Jun N-terminal kinase (JNK) 2 and 3 inhibitors with in vitro CNS-like pharmacokinetic properties prevent neurodegeneration.

John-Michael Sauer, Zhao Ren, Dean R Artis, 2011, Bioorganic & medicinal chemistry letters.

Measuring NAD(+) levels in mouse blood and tissue samples via a surrogate matrix approach using LC-MS/MS.

P. Dragovich, B. Liederer, C. Hop, 2014, Bioanalysis.

In Vitro and In Vivo Evaluation of Amorphous Solid Dispersions Generated by Different Bench-Scale Processes, Using Griseofulvin as a Model Compound

Y. Ran, J. Lubach, H. Wong, 2013, The AAPS Journal.

THU0117 PHARMACOKINETICS AND SHORT-TERM SAFETY OF FILGOTINIB, A SELECTIVE JANUS KINASE 1 INHIBITOR, IN SUBJECTS WITH MODERATE HEPATIC IMPAIRMENT

A. Mathias, B. Kearney, Ann Qin, 2019, Poster Presentations.

Abstract DDT02-03: Discovery of GDC-0994, a potent and selective ERK1/2 inhibitor in early clinical development

S. Gould, M. Belvin, Peter Yin, 2014 .

Use of Transgenic Mouse Models to Understand the Oral Disposition and Drug-Drug Interaction Potential of Cobimetinib, a MEK Inhibitor

E. Choo, J. Ly, Ann Qin, 2015, Drug Metabolism and Disposition.